AstraZeneca announces CARES phase III clinical programme fails to meet primary endpoint in overall light chain amyloidosis population: Cambridge, UK Monday, June 1, 2026, 12:00 Hr ...
Free light chain (FLC) kappa and lambda Assays for Atellica ® NEPH 630*, BN TM II, and BN ProSpec ® Systems are developed for more reliable managment of patients with monoclonal gammopathies. Improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results